Mechanism explainers

Semax has a documented mechanism and a quarter-century of authorised use in Russia. Whether either of those things adds up to evidence a Western reader can actually check is a separate, unresolved question.

GHK-Cu drops sharply with age and does striking things to cells in a dish. Whether any of that survives contact with actual human skin is a separate, unresolved question.

Thymosin beta-4's actin-grabbing mechanism is well mapped in the lab. Whether an injected synthetic version actually speeds tendon repair in a human body is a question the published research has never actually asked.

The oral-versus-injectable debate for BPC-157 gets argued with total confidence online. The actual bioavailability data behind those arguments, in either direction, is worth checking before you pick a side.

TB-500 gets sold as an anti-inflammatory peptide. The animal studies behind that claim used a different molecule than the one in most vials, and nobody has tested whether timing during the wound's inflammatory window changes the outcome.

Every study on GHK-Cu's wound-healing chemistry stops at the fibroblast dish. What happens once a wound closes, in the weeks that actually build a scar, is a different, mostly untested question.

KPV, a three-amino-acid fragment of alpha-MSH, shows a consistent anti-inflammatory signal in cells and mice. No human trial has tested whether that mechanism, or its proposed MC1R selectivity, works the same way in a person.

TB-500's reputation rests on tendon anecdote, but the peer-reviewed record on thymosin beta-4 is overwhelmingly cardiac: actin sequestration, epicardial progenitor signaling, coronary angiogenesis. No human cardiac trial exists, and grey-market TB-500 may not match the molecule studied.

GHK-Cu has a plausible, multi-pathway mechanism for hair-follicle regeneration, but almost all the evidence is in vitro and animal-model work from the 1990s and 2000s. No human trial has tested it in hair, and the sole human RCT in skin found no effect.

BPC-157 is the repair peptide half the gym is talking about. Strip out the forum noise and the answer is simple: in animals it speeds healing by growing new blood supply into injured tissue. Here is what that could mean for you, how far the human proof goes, and what the FDA is about to review.

GHK-Cu is a copper-carrying peptide your body makes to repair itself, and makes less of as you age. Here's the plain-English answer: what it could do for you, why the biology is exciting, how far the human proof goes — and where the injectable form sits in the FDA's next compounding review.

Chronic, low-grade inflammation tracks with slower recovery, stiff joints, and how fast you age. Three peptides under FDA review — KPV, BPC-157, and GHK-Cu — each turn it down from a different direction. Here is what that could mean for you, and how far the human proof actually goes.

Most fat-loss peptides work by turning up your whole growth-hormone system and hoping the fat follows. AOD-9604 skips that and talks to the fat cell directly — a cleaner idea. Here is how the mechanism works, why your fat is a hormone-producing organ, and how far the human proof actually goes.

The thymus trained every immune cell you own, then started shrinking in your teens. Its slow fade is a big reason immunity gets weaker with age — and the reason a family of thymus-signal peptides is worth understanding. Here is the biology, in plain language.

You don't need a biology degree to judge peptide evidence yourself. You need five questions. Ask them of any study a seller quotes at you and the real signal pulls away from the sell — and the whole field gets more exciting once you can tell which promises have something under them.

Collagen is the scaffolding under your skin, tendons, and joints — and three peptides now in front of the FDA each lean on how your body builds it. Here is what that could mean for repair and ageing, why the biology is genuinely exciting, and how far the human proof actually goes.

Most peptides come as a vial and a needle for one reason — swallow them and your gut destroys them before they can work. Understanding how a peptide actually gets into your body is the single lens that tells you whether a product can work at all. Here is how it works, in plain English.

Your body has a switch for stress — it should flip on under load and off when it passes. When it stops flipping off, you get the wired-and-foggy version most men know. Here is how that switch works, and how two Russian peptides could help it behave.

Telomeres cap your chromosomes, and get shorter every time a cell divides. Reset that countdown and you'd slow ageing itself — the longevity holy grail. Here's the real biology, what could move it, and why telomere-lengthening as anti-ageing is still unproven in humans.

Repair runs on fresh plumbing — new blood vessels growing into damaged tissue. It's the mechanism three of the most-talked-about recovery peptides — BPC-157, TB-500 and GHK-Cu — are built on. Here's what that could mean for how you heal, and the one question the same biology always raises.

CJC-1295, ipamorelin, sermorelin, and tesamorelin share one job — getting your own pituitary to release more growth hormone, the repair-and-recovery signal that fades after your twenties. Here is the appeal, the two peptide families inside the class, and how far the human proof actually goes.

Your mitochondria don't just make energy — they send hormone-like signals that tell the body how to run, and the supply fades with age. Mitochondrial-derived peptides are that family. Here's what the class could do, how far proof goes, and where its most-studied member sits in July's FDA review.

BPC-157's reputation rests on one mechanism — it appears to build fresh blood supply into damaged tissue. Here is that mechanism in plain language, angiogenesis and nitric oxide made simple, what it could mean for recovery, how far the animal proof goes, and the FDA review set for July 2026.

Peptides are the short chains of amino acids your body already uses to send signals — repair this, burn that, grow here. Some are drugs you trust, like insulin. Others are early and genuinely exciting. Here is the plain map of what they are, what they might do for you, and where the science stands.

Selank is Russia's attempt at an anxiety peptide that takes the edge off without the sedation, the fog, or the dependence a benzodiazepine leaves you with. The early promise is real and genuinely interesting — here's what it could do for you, and how far the human proof actually goes.

Ipamorelin asks your own body to release a clean pulse of growth hormone — the recovery, sleep and body-composition signal — without the stress-hormone mess older compounds caused. Here's what that could mean for you, and how far the human proof actually goes.

CJC-1295 is engineered to make your own pituitary release growth hormone for days from a single shot — and unusually, a real human trial says it works. Here's what that could mean for recovery, sleep and body composition, how far the proof goes, and why one name hides two different compounds.

Sermorelin is the growth-hormone peptide with a real FDA past — and a clever way of working: it nudges your own gland to make more GH instead of overriding it. Here's what it could do for you, how far the human proof actually goes, and why its availability isn't waiting on the July FDA vote.

Selank and Semax get sold side by side as brain peptides, but they solve opposite problems — one calms, one sharpens. Here's what each could do for you, how far the Russian evidence actually goes, and why the July 2026 FDA review splits them apart.

DSIP (Emideltide on the FDA paperwork) is a peptide your body makes that peaks in your deepest sleep. The idea — hand it back to push deeper sleep and a steadier stress system — is genuinely interesting. Here is what it could do for you, and why the best human trial came back cold.

You've probably met ipamorelin as the second half of CJC-1295 and ipamorelin. On its own it's the quieter half — a small peptide built to ask your own body for a clean pulse of growth hormone. Here's what it could mean for you, why it earned the clean name, and how far the human proof goes.

Semax is a Russian brain peptide with an unusual credential — three decades of real clinical use in stroke care, not just a biohacker rumour. Here is what it could do across neuroprotection and focus, how far the proof runs, and its spot on the FDA's July 2026 PCAC docket.